Status: Recruiting
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Participants needed: 75
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Sling Therapeutics, Inc.Updated: Feb 25, 2025Locations: 2
Eligibility criteria
Subject who completed the 24-week double-mask period of VGN-TED-301 and are prop... [+3]
The exclusion criteria of protocol VGN-TED-301 also apply to this extension stud...